相关实验视频

Updated: May 2, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 3, 2013

通过动脉的化学栓塞结合lenvatinib和sintilimabvs lenvatinib单独在中间到高级的肝细胞癌中

Fei-Da Wu¹, Hai-Feng Zhou¹, Wei Yang¹

¹Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.

World journal of gastrointestinal oncology

|January 16, 2025

概括

在跨动脉化血栓化 (TACE) 过程中添加sintilimab和lenvatinib,显著改善了肝细胞癌 (HCC) 患者的治疗结果. 与单独使用伦瓦提尼布相比,这种组合疗法可以提高无进展生存率 (PFS) 和整体生存率 (OS).

科学领域:

肝病学和瘤学研究专注于先进的肝癌治疗方法.

背景情况:

肝细胞癌 (HCC) 具有有限的治疗选择和不良预后.
对于中期HCC的跨动脉化学栓塞 (TACE) 可以促进血管生成.
将TACE与伦瓦提尼布和像辛蒂利马布这样的免疫疗法结合起来是一个有前途的策略.

研究的目的:

为了比较TACE加伦瓦提尼布和辛蒂利马布 (TACE + SL) 与TACE加伦瓦提尼布单独 (TACE + L) 的疗效和安全性.
评估中期至晚期HCC患者的治疗结果.

主要方法:

在2019年9月至2022年9月期间,对57名中级晚期HCC患者进行了回顾性分析.
将TACE + SL与TACE + L组进行比较,并对倾向性得分进行匹配.
评估总生存 (OS),无进展生存 (PFS) 和客观反应率 (ORR);分析了不良事件.

主要成果:

与TACE + L.相比,TACE + SL组显示PFS (14.1个月 vs 9.6个月) 和OS (22.4个月 vs 14.1个月) 的中位数明显改善.
在TACE + SL组中观察到更高的客观响应率 (ORR) (70.0%与55.6%相比).
倾向性得分匹配证实了TACE + SL组中改善的PFS (14.6 vs 9.2个月) 和更好的OS的趋势.

结论:

在中度至高级的HCC中,TACE + SL疗法表现出比TACE + L更高的疗效.
添加sintilimab可能会增强治疗反应并改善生存结果.
需要进一步的研究来证实这些发现,并优化HCC的组合疗法.

关键词:

肝细胞癌是肝细胞癌.免疫治疗是一种免疫疗法.伦瓦提尼布 (Lenvatinib) 是一种药物.预后预后预测预测编程细胞死亡 1 编程细胞死亡这就是Sintilimab.通过动脉化学栓塞的跨动脉化疗.

更多相关视频

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Published on: May 2, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...